Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – What’s Next?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-high trading volume on Thursday. Approximately 608,157 shares changed hands during mid-day trading, an increase of 133% from the average daily volume of 260,611 shares. The stock last traded at $22.6575 and had previously closed at $21.52.

Analysts Set New Price Targets

CHGCY has been the subject of several recent research reports. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Chugai Pharmaceutical currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 1.3%

The stock’s 50-day moving average price is $20.72 and its 200 day moving average price is $24.45. The company has a market cap of $73.74 billion, a P/E ratio of 23.34 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Tuesday, October 27th. The company reported $0.27 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.63% and a return on equity of 24.91%. The firm had revenue of $2.54 billion for the quarter, compared to the consensus estimate of $2.29 billion. Analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.